Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

OTHER 4INDUSTRY 4OTHER_GOV 2NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 6Plasma cell 2Sarcoma 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Multiple Myeloma 207Neoplasms, Plasma Cell 73Lymphoma 71Lymphoma, Non-Hodgkin 48Leukemia, Lymphocytic, Chronic, B-Cell 47Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Leukemia 37Hodgkin Disease 37Lymphoma, Follicular 36Lymphoma, Mantle-Cell 35Lymphoma, Large B-Cell, Diffuse 35Hematologic Neoplasms 34Leukemia, Myeloid, Acute 33Lymphoma, B-Cell, Marginal Zone 32Burkitt Lymphoma 32Myelodysplastic Syndromes 31Lymphoma, Large-Cell, Immunoblastic 31Myeloproliferative Disorders 26Leukemia, Myeloid, Chronic-Phase 22Leukemia, Myeloid, Accelerated Phase 22Blast Crisis 21Lymphoma, T-Cell, Cutaneous 19Leukemia, Hairy Cell 19Primary Myelofibrosis 18Waldenstrom Macroglobulinemia 17Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Leukemia, Myelomonocytic, Chronic 16Sezary Syndrome 15Mycosis Fungoides 15Lymphoma, Large-Cell, Anaplastic 15

Interventions

Lenalidomide 2Dexamethasone 1Calcium Dobesilate 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Disease Progression × Plasma cell × Clear all
NCT01109004 2021-12-09

BMT CTN 0702

National Heart, Lung, and Blood Institute (NHLBI)

Phase 3 Completed
758 enrolled 21 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma, Disease Progression

NCT02322320 2020-05-11

Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 3 Completed
273 enrolled 16 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡